Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) saw unusually-strong trading volume on Tuesday . Approximately 10,877,230 shares were traded during trading, an increase of 1,546% from the previous session’s volume of 660,936 shares.The stock last traded at $0.66 and had previously closed at $0.47.

Separately, S&P Equity Research reduced their price target on Repros Therapeutics from $0.49 to $0.39 in a report on Monday, November 20th.

Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.24. Repros Therapeutics had a negative return on equity of 894.22% and a negative net margin of 4,242.73%. The firm had revenue of $0.30 million for the quarter.

A hedge fund recently raised its stake in Repros Therapeutics stock. Allegis Investment Advisors LLC lifted its stake in Repros Therapeutics Inc. (NASDAQ:RPRX) by 8.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 398,792 shares of the biotechnology company’s stock after purchasing an additional 32,602 shares during the period. Allegis Investment Advisors LLC owned 1.49% of Repros Therapeutics worth $183,000 at the end of the most recent reporting period. 13.59% of the stock is owned by institutional investors and hedge funds.

WARNING: “Repros Therapeutics (RPRX) Sees Large Volume Increase” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/repros-therapeutics-rprx-sees-large-volume-increase/1760030.html.

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.